πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Kintara Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

KVD001, sebetralstat, KVD824, Factor XIIa

Kal Vista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with unmet needs, including hereditary angioedema and diabetic macular edema.

Tags: Clinical Trials, Diabetic Macular Edema, Hereditary Angioedema, Pharmaceuticals, Protease Inhibitors

Symbol: KALV

Recent Price: $8.39

Industry: Biotechnology

CEO: Mr. Benjamin L. Palleiko

Sector: Healthcare

Employees: 150

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 857 999 0075

Leadership

  • Albert Cha, Member of Board of Directors
  • William (Bill) Fairey, Member of Board of Directors
  • Benjamin L. Palleiko, Chief Executive Officer and Director
  • Brian J. G. Pereira, Member of Board of Directors
  • Nancy Stuart, Member of Board of Directors
  • Pat Treanor, Member of Board of Directors
  • Edward W. Unkart, Member of Board of Directors

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

rezafungin acetate

Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology. Their lead product candidate is rezafungin acetate, a novel echinocandin antifungal for treating invasive fungal infections.

Tags: Cloudbreak platform, anti-infectives, antifungal, biotechnology, infectious diseases, oncology, rezafungin acetate

Symbol: CDTX

Recent Price: $25.25

Industry: Biotechnology

CEO: Dr. Jeffrey L. Stein Ph.D.

Sector: Healthcare

Employees: 69

Address: 6310 Nancy Ridge Drive, San Diego, CA 92121

Phone: 858 752 6170

Last updated: 2024-12-31

Erasca, Inc.

Erasca, Inc. logo
Market Cap: Medium
Employees: Low

ERAS-007, ERAS-601, ERAS-801

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Tags: ERAS-007, ERAS-601, ERAS-801, RAS/MAPK, biopharmaceutical, cancers

Symbol: ERAS

Recent Price: $2.55

Industry: Biotechnology

CEO: Dr. Jonathan E. Lim M.D.

Sector: Healthcare

Employees: 126

Address: 10835 Road to the Cure, San Diego, CA 92121

Phone: 858 465 6511

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

INT230-6

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.

Tags: biotechnology, cancer treatment, clinical trials, collaboration, solid tumors

Symbol: INTS

Recent Price: $1.82

Industry: Biotechnology

CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.

Sector: Healthcare

Employees: 5

Address: 61 Wilton Road, Westport, CT 06880

Phone: 203 221 7381

Leadership

  • Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
  • Joseph Talamo, CPA, Chief Financial Officer
  • James M. Ahlers, Executive Vice President
  • Brian Schwartz, MD, Executive VP, Clinical Development
  • John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
  • Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
  • Doranne Frano, Regulatory Affairs and Quality Control
  • Daniel J. Donovan, Board Member and Chief Executive Officer
  • Tom Dubin, Board Member
  • Mark A. Goldberg, MD, Board Member
  • Emer Leahy, Ph.D., Board Member

Last updated: 2024-12-31

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KIO-301

Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.

Tags: clinical trials, ophthalmic diseases, ophthalmology, pharmaceuticals, vision restoration

Symbol: KPRX

Recent Price: $3.30

Industry: Biotechnology

CEO: Dr. Brian M. Strem Ph.D.

Sector: Healthcare

Employees: 12

Address: 1371 East 2100 South, Salt Lake City, UT 84105

Phone: 781 788 8869

Last updated: 2024-12-31

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. logo
Market Cap: High
Employees: Low

KER-050

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets cytopenias, including anemia and thrombocytopenia.

Tags: biopharmaceutical, clinical-stage, cytopenias, hematological disorders, musculoskeletal disorders

Symbol: KROS

Recent Price: $15.64

Industry: Biotechnology

CEO: Dr. Jasbir S. Seehra Ph.D.

Sector: Healthcare

Employees: 149

Address: 99 Hayden Avenue, Lexington, MA 02421

Phone: 617 314 6297

Leadership

  • Jasbir Seehra, Ph.D., Board Member
  • Keith Regnante, M.B.A., Chief Financial Officer
  • Christopher Rovaldi, President, Chief Operating Officer
  • Esther Cho, J.D., Senior Vice President, General Counsel
  • John Oram, M.B.A., Senior Vice President, Program and Portfolio Management
  • Robin Wagner, Senior Vice President, Human Resources
  • Carl L. Gordon, Ph.D., C.F.A., Board Member
  • Jean-Jacques BienaimΓ©, M.B.A., Lead Independent Director
  • Nima Farzan, M.B.A., Board Member
  • Mary Ann Gray, Ph.D., Board Member
  • Tomer Kariv, J.D., Board Member
  • Julius Knowles, M.B.A., Board Member
  • Ran Nussbaum, Board Member
  • Alpna Seth, Ph.D., Board Member

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Kura Oncology, Inc.

Kura Oncology, Inc. logo
Market Cap: High
Employees: Low

ziftomenib and tipifarnib

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.

Tags: biopharmaceutical, cancer treatment, clinical trials, hematologic, leukemia, small molecule, solid tumors

Symbol: KURA

Recent Price: $8.51

Industry: Biotechnology

CEO: Dr. Troy Edward Wilson J.D., Ph.D.

Sector: Healthcare

Employees: 142

Address: 12730 High Bluff Drive, San Diego, CA 92130

Phone: 858 500 8800

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Protara Therapeutics, Inc.

Protara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

N/A

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

No tags available.

Symbol: TARA

Recent Price: $5.28

Industry: Biotechnology

CEO: Mr. Jesse Shefferman

Sector: Healthcare

Employees: 26

Address: 345 Park Avenue South, New York, NY 10010

Phone: 646 844 0337

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Verastem, Inc.

Verastem, Inc. logo
Market Cap: Low
Employees: Low

VS-6766

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for cancer treatment, with products such as VS-6766 and trials like RAMP 201 and 202 targeting various cancer types.

Tags: MEK, RAF, RAMP 201, RAMP 202, VS-6766, biopharmaceutical, cancer treatment, drug development

Symbol: VSTM

Recent Price: $3.67

Industry: Biotechnology

CEO: Mr. Daniel W. Paterson

Sector: Healthcare

Employees: 73

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 781 292 4200

Last updated: 2024-12-31

Nektar Therapeutics

Nektar Therapeutics logo
Market Cap: Low
Employees: Low

Bempegaldesleukin

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, medicines, oncology

Symbol: NKTR

Recent Price: $0.94

Industry: Biotechnology

CEO: Mr. Howard W. Robin

Sector: Healthcare

Employees: 137

Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158

Phone: 415 482 5300

Leadership

  • Howard W. Robin, President & Chief Executive Officer
  • Robert Bacci, Senior Vice President, HR and Facilities Operations
  • Sandra Gardiner, Chief Financial Officer
  • Jennifer Ruddock, Chief Business Officer
  • Mary Tagliaferri, M.D., Chief Medical Officer
  • Mark A. Wilson, Chief Legal Officer
  • Jonathan Zalevsky, Ph.D., Chief Research & Development Officer

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Nana-val

Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies, with a lead product candidate Nana-val in clinical trials for Epstein-Barr virus-positive lymphoma and other related conditions.

Tags: EBV+ lymphoma, biotech, clinical trials, oncology, pharmaceuticals, virus-associated malignancies

Symbol: VIRX

Recent Price: $0.16

Industry: Biotechnology

CEO: Mr. Mark Andrew Rothera

Sector: Healthcare

Employees: 40

Address: 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA 92007

Phone: 858 400 8470

Leadership

  • Mark Rothera, President and Chief Executive Officer
  • Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer
  • Ayman Elguindy, Ph.D., Chief Scientific Officer
  • Michael Faerm, MBA, Chief Financial Officer
  • Cheryl Madsen, Senior Vice President, Regulatory
  • Patric Nelson, MBA, Senior Vice President, Business Development & Corporate Strategy
  • Biljana Nadjsombati, Pharm.D., Senior Vice President, Pharmaceutical Development
  • Violetta Akopian, Ph.D., Vice President, Quality Assurance
  • Ruby Cheema, Vice President, Portfolio and Program Management
  • Mark A. McCamish, M.D., Ph.D., Strategic Advisor
  • Roger J. Pomerantz, M.D., Chairman of the Board
  • Jane F. Barlow, M.D., MPH, MBA, Director
  • Flavia Borellini, Ph.D., Director
  • Jane Chung, R.Ph., Director
  • Thomas E. Darcy, CPA, Director
  • Sam Murphy, Ph.D., Director
  • Ivor Royston, M.D., Director
  • Stephen Rubino, Ph.D., MBA, Director
  • Barry J. Simon, M.D., Director
  • Douglas V. Faller, M.D., Ph.D., Scientific Founder and Chairman, Scientific Advisory Board
  • Robert Baiocchi, M.D., Ph.D., Scientific Advisor
  • Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath, Scientific Advisor
  • Carl June, M.D., Scientific Advisor
  • Shannon Kenney, M.D., Scientific Advisor
  • Ronald Levy, M.D., Scientific Advisor
  • Pierluigi Porcu, M.D., Scientific Advisor
  • Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR, Scientific Advisor
  • Lawrence Young, Ph.D., Scientific Advisor

Last updated: 2024-12-31